etoposide and cabazitaxel
etoposide has been researched along with cabazitaxel in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Chao, OS; Goodman, OB | 1 |
Reviews
1 review(s) available for etoposide and cabazitaxel
| Article | Year |
|---|---|
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
Other Studies
1 other study(ies) available for etoposide and cabazitaxel
| Article | Year |
|---|---|
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |